Stephen Daw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephen Daw has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Georgina W. Hall
Children’s Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Trust
2 shared publications - Cindy L. Schwartz
MD Anderson Cancer Center
1 shared publication Cindy Schwartz
Hasbro Children’s Hospital
1 shared publicationHamish Wallace
Department of Haematology and Oncology, Royal Hospital for Sick Children, Edinburgh, UK
1 shared publicationLouis S. Constine
University of Rochester Medical Center
1 shared publication- Louis S. Constine
Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, NY
1 shared publication
Latest Publications
- 5 December 2014
- Published by Springer Nature
- p. 253-270
Pediatric Hodgkin Lymphoma
- 7 December 2010
- Published by Wiley in British Journal of Haematology
- Vol. 152 (3) , 249-260
Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents
Summary: There are a number of options for salvage treatment in children and adolescents with relapsed and refractory classical Hodgkin Lymphoma. These include salvage with standard dose chemotherapy, high dose chemotherapy with autologous stem cell transplant, allogeneic stem cell transplant or other novel approach. Radiotherapy has an important role in the salvage of some patients as part of a combined modality approach. This review outlines these salvage approaches and discusses whether the evidence from paediatric studies justifies a risk‐adapted approach to salvage for individual patients or whether all patients should receive consolidation with high dose chemotherapy and autologous stem cell transplantation, which is often described as standard salvage management in adults. The important prognostic factors and how these may be used to allocate patients to standard versus high dose chemotherapy regimens are discussed. The role of allogeneic transplantation, novel agents and late effects will also be discussed.
- 7 December 2010
- Published by Wiley in British Journal of Haematology
- Vol. 152 (3) , 249-260
Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents
Summary: There are a number of options for salvage treatment in children and adolescents with relapsed and refractory classical Hodgkin Lymphoma. These include salvage with standard dose chemotherapy, high dose chemotherapy with autologous stem cell transplant, allogeneic stem cell transplant or other novel approach. Radiotherapy has an important role in the salvage of some patients as part of a combined modality approach. This review outlines these salvage approaches and discusses whether the evidence from paediatric studies justifies a risk‐adapted approach to salvage for individual patients or whether all patients should receive consolidation with high dose chemotherapy and autologous stem cell transplantation, which is often described as standard salvage management in adults. The important prognostic factors and how these may be used to allocate patients to standard versus high dose chemotherapy regimens are discussed. The role of allogeneic transplantation, novel agents and late effects will also be discussed.
- 18 August 2010
- Published by Springer Nature
- p. 211-225
Pediatric Hodgkin Lymphoma